Novartis Ag (NVS) Interest Expenses (2009 - 2026)

Novartis Ag (NVS) has 16 years of Interest Expenses data on file, last reported at -$343.0 million in Q1 2026.

• Quarterly Interest Expenses fell 27.04% year-over-year to -$343.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 15.36% YoY) and the FY2025 annual result came in at $1.1 billion, up 13.72% from the prior year.
• Interest Expenses retreated to -$343.0 million in Q1 2026 per NVS's latest filing, from -$304.0 million in the prior quarter.
• The five-year high for Interest Expenses was -$200.0 million in Q1 2023, with the low at -$343.0 million in Q1 2026.
• Average Interest Expenses over 5 years is -$244.9 million, with a median of -$222.0 million recorded in 2023.
• Year-over-year, Interest Expenses rose 0.5% in 2023 and retreated 27.04% in 2026.
• Novartis Ag's Interest Expenses stood at -$207.0 million in 2022, then slipped by 4.83% to -$217.0 million in 2023, then declined by 26.73% to -$275.0 million in 2024, then decreased by 10.55% to -$304.0 million in 2025, then decreased by 12.83% to -$343.0 million in 2026.
• Business Quant data shows NVS's Interest Expenses at -$343.0 million in Q1 2026, -$304.0 million in Q4 2025, and -$281.0 million in Q3 2025.